$185 Million is the total value of Stonepine Capital Management, LLC's 27 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REPH | Sell | Recro Pharma, Inc. | $12,863,000 | -48.8% | 1,829,669 | -36.3% | 6.95% | -50.9% |
| VCEL | Sell | Vericel Corp | $9,836,000 | +7.6% | 2,980,570 | -8.7% | 5.31% | +3.1% |
| AVDL | Sell | Avadel Pharmaceuticals PLCspons adr | $8,249,000 | +13.3% | 747,863 | -0.6% | 4.45% | +8.5% |
| CRME | Sell | Cardiome Pharma Corp | $7,212,000 | -13.1% | 1,595,549 | -42.1% | 3.89% | -16.7% |
| ALR | Sell | Alere Inc. | $5,019,000 | -54.1% | 100,000 | -63.6% | 2.71% | -56.0% |
| SCLN | Sell | Sciclone Pharmaceuticals, Inc. | $2,379,000 | -85.4% | 216,307 | -87.0% | 1.28% | -86.0% |
| TRIB | Sell | Trinity Biotech PLC - SPON ADRspons adr | $1,872,000 | -10.7% | 311,994 | -11.3% | 1.01% | -14.5% |
| ALIM | Sell | Alimera Sciences, Inc | $257,000 | -92.9% | 184,827 | -92.8% | 0.14% | -93.2% |
| AVIR | Exit | Aviragen Therapeutics, Inc. | $0 | – | -314,421 | -100.0% | -0.12% | – |
| XOMA | Exit | XOMA CORP | $0 | – | -87,960 | -100.0% | -0.35% | – |
| EBS | Exit | Emergent Biosolutions Inc | $0 | – | -54,505 | -100.0% | -0.89% | – |
| Exit | Aegerion Pharmaceuticals, Inc.note | $0 | – | -16,600,000 | -100.0% | -7.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.